Arovella Therapeutics Limited (FRA:E4NA)

Market Cap	48.30M -8.5%
Revenue (ttm)	1.82M -6.9%
Net Income	-4.50M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0390
Previous Close	0.0390
Day's Range	0.0390 - 0.0390
52-Week Range	0.0355 - 0.0560
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Arovella Therapeutics

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly know...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 1999
• Employees: 27
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: E4NA

Financial Performance

In fiscal year 2025, Arovella Therapeutics's revenue was 3.44 million, an increase of 76.22% compared to the previous year's 1.95 million. Losses were -7.51 million, -14.14% less than in 2024.

Financial numbers in AUD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error